Back to main

KYTHERA Biopharma prices upsized deal at $16, at high end of the range

Posted
10/11/2012 8:36:00 AM
By: Renaissance Capital
Referenced Stocks:KYTH

KYTHERA Biopharmaceuticals, which is commercializing an injectable treatment for double chins with Bayer, raised $70 million by offering 4.4 million shares at $16, at high end of the range of $14 to $16. The 4.4 million shares offered was 10% more than originally anticipated. KYTHERA Biopharma plans to list on the NASDAQ under the symbol KYTH. J.P. Morgan and Goldman Sachs acted as lead managers on the deal.